Latest Insider Transactions at Praxis Precision Medicines, Inc. (PRAX)
This section provides a real-time view of insider transactions for Praxis Precision Medicines, Inc. (PRAX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Praxis Precision Medicines, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Praxis Precision Medicines, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 09
2022
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+19.81%
|
$10,000
$1.76 P/Share
|
|
Jun 08
2022
|
Dean J Mitchell Director |
BUY
Open market or private purchase
|
Direct |
25,000
+50.0%
|
$25,000
$1.81 P/Share
|
|
Jun 08
2022
|
Marcio Souza Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
27,000
+12.49%
|
$27,000
$1.85 P/Share
|
|
May 13
2022
|
Nicole Sweeny Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,587
+5.78%
|
$20,696
$8.8 P/Share
|
|
May 13
2022
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,585
+7.82%
|
$20,680
$8.8 P/Share
|
|
May 13
2022
|
Marcio Souza Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,392
+0.85%
|
$11,136
$8.8 P/Share
|
|
May 13
2022
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,557
+8.26%
|
$20,456
$8.8 P/Share
|
|
May 13
2022
|
Alex Nemiroff General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
2,202
+6.47%
|
$17,616
$8.8 P/Share
|
|
Feb 12
2022
|
Lauren Mastrocola Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
584
-2.21%
|
$7,008
$12.85 P/Share
|
|
Feb 12
2022
|
Alex Nemiroff General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
755
-2.48%
|
$9,060
$12.85 P/Share
|
|
Feb 12
2022
|
Bernard Ravina Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,057
-2.98%
|
$36,684
$12.85 P/Share
|
|
Feb 12
2022
|
Nicole Sweeny Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,233
-3.02%
|
$14,796
$12.85 P/Share
|
|
Jan 07
2022
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+46.24%
|
-
|
|
Jan 07
2022
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+18.51%
|
-
|
|
Jan 07
2022
|
Alex Nemiroff General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+37.19%
|
-
|
|
Jan 07
2022
|
Bernard Ravina Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+17.67%
|
-
|
|
Jan 07
2022
|
Marcio Souza Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,000
+31.52%
|
-
|
|
Jan 07
2022
|
Nicole Sweeny Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+37.04%
|
-
|
|
Oct 06
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
400,000
-100.0%
|
$6,800,000
$17.5 P/Share
|
|
Oct 05
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,946
-5.65%
|
$454,974
$19.15 P/Share
|
|
Oct 01
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,600
-5.06%
|
$429,400
$19.13 P/Share
|
|
Aug 31
2021
|
Timothy Edwin Kelly Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,905
+50.0%
|
$74,195
$19.48 P/Share
|
|
Aug 23
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
352,396
-22.09%
|
$6,695,524
$19.52 P/Share
|
|
Aug 18
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,000
-0.37%
|
$45,000
$15.88 P/Share
|
|
Aug 18
2021
|
Marcio Souza Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,542
+9.91%
|
$143,130
$15.79 P/Share
|
|
Aug 12
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,060
-1.24%
|
$130,780
$13.92 P/Share
|
|
Aug 11
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
17,222
-2.08%
|
$258,330
$15.03 P/Share
|
|
Aug 03
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,300
-2.62%
|
$312,200
$14.99 P/Share
|
|
Aug 02
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
40,000
-4.49%
|
$600,000
$15.78 P/Share
|
|
Jul 30
2021
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,854
-1.75%
|
$237,810
$15.68 P/Share
|
|
May 13
2021
|
William D Young Director |
BUY
Other acquisition or disposition
|
Direct |
28,473
+50.0%
|
-
|
|
May 12
2021
|
Gregory Norden Director |
BUY
Other acquisition or disposition
|
Direct |
2,826
+50.0%
|
-
|
|
May 12
2021
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
2,700,000
-35.55%
|
-
|
|
Feb 12
2021
|
Bernard Ravina Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,512
+23.33%
|
-
|
|
Feb 12
2021
|
Marcio Souza Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,800
+40.6%
|
-
|
|
Feb 12
2021
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+28.65%
|
-
|
|
Feb 12
2021
|
Alex Nemiroff General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
12,400
+50.0%
|
-
|
|
Feb 12
2021
|
Nicole Sweeny Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,800
+50.0%
|
-
|
|
Jan 04
2021
|
Bernard Ravina Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+44.55%
|
$90,000
$2.27 P/Share
|
|
Nov 10
2020
|
Marcio Souza Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,846
+13.59%
|
$99,996
$26.08 P/Share
|
|
Nov 02
2020
|
Lauren Mastrocola Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,218
+50.0%
|
$36,654
$3.3 P/Share
|
|
Oct 20
2020
|
Bsof Parallel Master Fund L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
7,800,553
+22.66%
|
-
|
|
Oct 20
2020
|
Clarus Lifesciences Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
7,800,553
+22.66%
|
-
|
|
Oct 20
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,442,080
+50.0%
|
-
|
|
Oct 20
2020
|
Stefan Vitorovic Director |
BUY
Conversion of derivative security
|
Indirect |
2,689,329
+50.0%
|
-
|
|
Oct 20
2020
|
Marcio Souza Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,604
+50.0%
|
-
|